ECSP10010721A - Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida - Google Patents

Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida

Info

Publication number
ECSP10010721A
ECSP10010721A EC2010010721A ECSP10010721A ECSP10010721A EC SP10010721 A ECSP10010721 A EC SP10010721A EC 2010010721 A EC2010010721 A EC 2010010721A EC SP10010721 A ECSP10010721 A EC SP10010721A EC SP10010721 A ECSP10010721 A EC SP10010721A
Authority
EC
Ecuador
Prior art keywords
nifurtimox
treatment
diseases caused
trichomonadida
histomoniasis
Prior art date
Application number
EC2010010721A
Other languages
English (en)
Inventor
Gisela Greif
Robrecht Froyman
Achim Harder
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP10010721A publication Critical patent/ECSP10010721A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonas, tales como, por ejemplo, la histomoniasis, particularmente en pavos.
EC2010010721A 2008-07-02 2010-12-27 Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida ECSP10010721A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008031283A DE102008031283A1 (de) 2008-07-02 2008-07-02 Neue Bekämpfungsmöglichkeit von durch Trichomonadida hervorgerufenen Krankheiten

Publications (1)

Publication Number Publication Date
ECSP10010721A true ECSP10010721A (es) 2011-01-31

Family

ID=41092164

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010721A ECSP10010721A (es) 2008-07-02 2010-12-27 Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida

Country Status (26)

Country Link
US (1) US8440613B2 (es)
EP (1) EP2310017B1 (es)
JP (1) JP5571659B2 (es)
KR (1) KR20110031360A (es)
CN (1) CN102083440B (es)
AR (1) AR072426A1 (es)
AU (1) AU2009266124B2 (es)
CA (1) CA2729727A1 (es)
CL (1) CL2010001594A1 (es)
CO (1) CO6321268A2 (es)
CR (1) CR20110023A (es)
DE (1) DE102008031283A1 (es)
DK (1) DK2310017T3 (es)
DO (1) DOP2010000406A (es)
EC (1) ECSP10010721A (es)
ES (1) ES2415231T3 (es)
IL (1) IL209999A0 (es)
MX (1) MX2010014444A (es)
NI (1) NI201100009A (es)
PE (1) PE20110370A1 (es)
PL (1) PL2310017T3 (es)
RU (1) RU2538712C2 (es)
SV (1) SV2011003784A (es)
UA (1) UA103197C2 (es)
WO (1) WO2010000398A1 (es)
ZA (1) ZA201009226B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2633855A1 (en) * 2012-03-01 2013-09-04 Veterinärmedizinische Universität Wien Protease inhibitors for treating Trichomonas gallinae infections
CN107835818B (zh) 2015-05-20 2022-04-29 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
KR20220003663A (ko) 2015-12-28 2022-01-10 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 뎁시펩티드 화합물
JP6085706B1 (ja) * 2016-03-31 2017-02-22 株式会社ポーラファルマ 抗トリトリコモナス剤
EP3541789A1 (en) 2016-11-16 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1170957B (de) 1962-11-23 1964-05-27 Bayer Ag Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten
NO176766C (no) * 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
CA2132199C (en) 1992-03-17 2000-01-18 Hitoshi Nishiyama Depsipeptide derivative, production thereof and use thereof
DE4317458A1 (de) * 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
CN1073560C (zh) 1993-02-19 2001-10-24 明治制果株式会社 环缩酚酸肽pf1022衍生物
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317432A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
US5646244A (en) 1993-09-06 1997-07-08 Fujisawa Pharmaceutical Co., Ltd. Cyclodepsipeptide compound
DE4401389A1 (de) 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
CN1071323C (zh) * 1995-06-30 2001-09-19 藤泽药品工业株式会社 缩肽衍生物或其盐的制造方法
NZ318515A (en) 1995-09-22 2000-05-26 Bayer Ag Cyclodepsipeptide PF1022 derivatives and compositions thereof
DE19545639A1 (de) 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
UA5478U (uk) * 2004-06-21 2005-03-15 Ігор Едуардович Лук'янов Спосіб лікування хворих на урогенітальний трихомоніаз
ZA200704784B (en) * 2004-11-12 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases

Also Published As

Publication number Publication date
EP2310017B1 (de) 2013-05-15
ES2415231T3 (es) 2013-07-24
AU2009266124A1 (en) 2010-01-07
MX2010014444A (es) 2011-02-22
DE102008031283A1 (de) 2010-01-07
ZA201009226B (en) 2012-03-23
DK2310017T3 (da) 2013-07-01
JP2011526264A (ja) 2011-10-06
US20110118176A1 (en) 2011-05-19
US8440613B2 (en) 2013-05-14
JP5571659B2 (ja) 2014-08-13
CO6321268A2 (es) 2011-09-20
KR20110031360A (ko) 2011-03-25
RU2011103476A (ru) 2012-08-10
AR072426A1 (es) 2010-08-25
CN102083440A (zh) 2011-06-01
DOP2010000406A (es) 2011-01-15
PL2310017T3 (pl) 2013-08-30
EP2310017A1 (de) 2011-04-20
CA2729727A1 (en) 2010-01-07
AU2009266124B2 (en) 2015-03-19
PE20110370A1 (es) 2011-06-22
RU2538712C2 (ru) 2015-01-10
SV2011003784A (es) 2011-05-20
WO2010000398A1 (de) 2010-01-07
CR20110023A (es) 2011-05-10
IL209999A0 (en) 2011-02-28
UA103197C2 (uk) 2013-09-25
CL2010001594A1 (es) 2011-05-06
NI201100009A (es) 2011-08-10
CN102083440B (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
CL2016001733A1 (es) Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12.
DOP2014000093A (es) Compuestos con actividad nematicida
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2019003738A (es) Compuestos antivirales.
CO6771447A2 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CR20140183A (es) Compuestos con actividad nematicida
CO6640285A2 (es) 5-alquinil-pirimidinas
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
GEP201706710B (en) Imidazopyridazine derivatives as gabaa receptor modulators
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
MX2013001612A (es) Moduladores de trpv3 novedosos.
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
UY34407A (es) Nuevos moduladores de trpv3
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas